Loading
TET1 (Methylcytosine dioxygenase TET1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Hepatocellular carcinoma, Testicular germ cell tumours and 5 more.
Dioxygenase that plays a key role in active DNA demethylation, by catalysing the sequential oxidation of the modified genomic base 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC). In addition to its role in DNA demethylation, plays a more general role in chromatin regulation by recruiting histone modifying protein complexes to alter histone marks and chromatin accessibility, leading to both activation and repression of gene expression. Plays therefore a role in many biological processes, including stem cell maintenance, T- and B-cell development, inflammation regulation, genomic imprinting, neural activity or DNA repair.
CIViC holds 1 clinical evidence item and 0 assertions across 2 variants, naming Immune Checkpoint Inhibitor. Open Targets scores its association with cancer at 0.69 (direct and indirect evidence; datatypes literature 0.99, animal model 0.32, genetic association 0.00, somatic mutation 0.89). IntOGen calls it a driver in 8 cohorts (1 activating, 7 loss-of-function), covering Colon Adenocarcinoma, Glioblastoma Multiforme, Hepatocellular Carcinoma, Medulloblastoma, Mixed Germ Cell Tumour, Nasopharyngeal Carcinoma and others.
In plain words · TET1 (Methylcytosine dioxygenase TET1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Hepatocellular carcinoma, Testicular germ cell tumours and 5 more.
TET1 (Methylcytosine dioxygenase TET1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Hepatocellular carcinoma, Testicular germ cell tumours and 5 more.
Dioxygenase that plays a key role in active DNA demethylation, by catalysing the sequential oxidation of the modified genomic base 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC).
No product in this corpus aims at TET1 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance) and a fusion partner (UniProt records a translocation), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA TET1: RNA low tissue specificity; no normal tissue stained high. Distribution: 8 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Colorectal cancer, Hepatocellular carcinoma, Testicular germ cell tumours, Nasopharyngeal carcinoma, Renal cell carcinoma, Gastric & gastro-oesophageal junction cancer, Skin cancer (all types) and more); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q8NFU7; CIViC gene TET1; IntOGen TET1; Human Protein Atlas TET1 tissue; Open Targets ENSG00000138336 associations
First described 2000. Earliest sequence paper UniProt cites for the protein: Nagase et al, DNA Res, 2000, "Prediction of the coding sequences of unidentified human genes. XIX. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro". Source.
Sources: HGNC HGNC:29484 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q8NFU7 (protein name, function text, keywords and locations (REST API)); CIViC gene TET1 (1 evidence items, 0 assertions, 2 variants; diseases: Cancer (GraphQL API, CC0)); Open Targets ENSG00000138336 (association with cancer (MONDO_0004992) 0.69; per-cancer scores at or above 0.5: colorectal cancer 0.55, ovarian cancer 0.52, melanoma 0.52, skin cancer 0.56, biliary tract cancer 0.51 (GraphQL API, CC0)); IntOGen TET1 (driver in 8 cohorts (Act 1, LoF 7); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Dioxygenase that plays a key role in active DNA demethylation, by catalysing the sequential oxidation of the modified genomic base 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC). In addition to its role in DNA demethylation, plays a more general role in chromatin regulation by recruiting histone modifying protein complexes to alter histone marks and chromatin accessibility, leading to both activation and repression of gene expression. Plays therefore a role in many biological processes, including stem cell maintenance, T- and B-cell development, inflammation regulation, genomic imprinting, neural activity or DNA repair. Involved in the balance between pluripotency and lineage commitment of cells and plays a role in embryonic stem cells maintenance and inner cell mass cell specification. Together with QSER1, plays an essential role in the protection and maintenance of transcriptional and developmental programs to inhibit the binding of DNMT3A/3B and therefore de novo methylation. May play a role in pancreatic beta-cell specification during development. Location: Nucleus; Chromosome (UniProt). Locus 10q21.3 (HGNC).
RNA: low tissue specificity, detected in some normal tissues.
No normal tissue stained high.
RNA cancer enriched: Testicular Germ Cell Tumor 15 pTPM.
No cancer sample stained medium or high.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"TET1" OR ABSTRACT:"TET1" OR TITLE:"tet methylcytosine dioxygenase 1" OR ABSTRACT:"tet methylcytosine dioxygenase 1" OR TITLE:"Methylcytosine dioxygenase TET1" OR ABSTRACT:"Methylcytosine dioxygenase TET1" OR TITLE:"KIAA1676" OR ABSTRACT:"KIAA1676" OR TITLE:"bA119F7.1" OR ABSTRACT:"bA119F7.1" OR TITLE:"CXXC6" OR ABSTRACT:"CXXC6") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TET1, not a curated reading list.
Shares Nasopharyngeal carcinoma, Skin cancer (all types), Hepatocellular carcinoma, CIViC.
Shares Nasopharyngeal carcinoma, Skin cancer (all types), Hepatocellular carcinoma, IntOGen.
Shares Nasopharyngeal carcinoma, Skin cancer (all types), CIViC, IntOGen.
Shares Nasopharyngeal carcinoma, Renal cell carcinoma, Skin cancer (all types), CIViC.
Shares Nasopharyngeal carcinoma, Skin cancer (all types), IntOGen, Open Targets Platform.
Shares Nasopharyngeal carcinoma, Skin cancer (all types), IntOGen, Open Targets Platform.
Shares Nasopharyngeal carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.
Shares Nasopharyngeal carcinoma, CIViC, IntOGen, Open Targets Platform.